Biotecnol is committed in building value by developing a diverse pipeline of antibody products to address unmet healthcare needs. Biotecnol has its own integrated capabilities, know-how, expertise and proprietary technologies to support the development of its own products.

 

These activities are leveraged by Biotecnol’s services capabilities, providing product & process development to clients, using its proprietary protein expression technologies, cell-line development capabilities, upstream and downstream processing, analytics and QC experience, for delivering GMP/GLP compliant processes for biomanufacturing, up to and including phase III products.

 

In addition, Biotecnol has a long track-record in supporting several partners wishing to gain access to its proprietary technologies and know-how in the competitive field of biopharmaceutical products development. Whenever needed, Biotecnol makes the most out of its development capabilities in order to create short-medium term revenues through collaborative programmes. Biotecnol has a significant track-record in carrying out early stage R&D, process and product development activities, and subsequently taking these products into production of clinical grade materials, according to current Good Manufacturing Practices (cGMP).

 

This business model generates valuable revenues for Biotecnol through contracted research and product & process development, whilst creating long-term value through the development of its internal pipeline of products.